{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li QS"],"funding":["DoD Alzheimer&apos;s Disease Neuroimaging Initiative","NIA NIH HHS","Alzheimer&apos;s Disease Neuroimaging Initiative","DoD Alzheimer's Disease Neuroimaging Initiative (US)"],"pagination":["191"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8518178"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["<h4>Background</h4>Identifying biomarkers associated with Alzheimer's disease (AD) progression may enable patient enrichment and improve clinical trial designs. Epigenome-wide association studies have revealed correlations between DNA methylation at cytosine-phosphate-guanine (CpG) sites and AD pathology and diagnosis. Here, we report relationships between peripheral blood DNA methylation profiles measured using Infinium® MethylationEPIC BeadChip and AD progression in participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.<h4>Results</h4>The rate of cognitive decline from initial DNA sampling visit to subsequent visits was estimated by the slopes of the modified Preclinical Alzheimer Cognitive Composite (mPACC; mPACC<sub>digit</sub> and mPACC<sub>trailsB</sub>) and Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) plots using robust linear regression in cognitively normal (CN) participants and patients with mild cognitive impairment (MCI), respectively. In addition, diagnosis conversion status was assessed using a dichotomized endpoint. Two CpG sites were significantly associated with the slope of mPACC in CN participants (P < 5.79 × 10<sup>-8</sup> [Bonferroni correction threshold]); cg00386386 was associated with the slope of mPACC<sub>digit</sub>, and cg09422696 annotated to RP11-661A12.5 was associated with the slope of CDR-SB. No significant CpG sites associated with diagnosis conversion status were identified. Genes involved in cognition and learning were enriched. A total of 19, 13, and 5 differentially methylated regions (DMRs) associated with the slopes of mPACC<sub>trailsB</sub>, mPACC<sub>digit</sub>, and CDR-SB, respectively, were identified by both comb-p and DMRcate algorithms; these included DMRs annotated to HOXA4. Furthermore, 5 and 19 DMRs were associated with conversion status in CN and MCI participants, respectively. The most significant DMR was annotated to the AD-associated gene PM20D1 (chr1: 205,818,956 to 205,820,014 [13 probes], Sidak-corrected P = 7.74 × 10<sup>-24</sup>), which was associated with both the slope of CDR-SB and the MCI conversion status.<h4>Conclusion</h4>Candidate CpG sites and regions in peripheral blood were identified as associated with the rate of cognitive decline in participants in the ADNI cohort. While we did not identify a single CpG site with sufficient clinical utility to be used by itself due to the observed effect size, a biosignature composed of DNA methylation changes may have utility as a prognostic biomarker for AD progression."],"journal":["Clinical epigenetics"],"pubmed_title":["Association of peripheral blood DNA methylation level with Alzheimer's disease progression."],"pmcid":["PMC8518178"],"funding_grant_id":["U24 AG021886","U19 AG024904","U01 AG024904","W81XWH-12-2-0012"],"pubmed_authors":["Saykin AJ","Waring JF","Vasanthakumar A","Li QS","Idler KB","Nho K","Alzheimer’s Disease Neuroimaging Initiative (ADNI)","Davis JW"],"additional_accession":[]},"is_claimable":false,"name":"Association of peripheral blood DNA methylation level with Alzheimer's disease progression.","description":"<h4>Background</h4>Identifying biomarkers associated with Alzheimer's disease (AD) progression may enable patient enrichment and improve clinical trial designs. Epigenome-wide association studies have revealed correlations between DNA methylation at cytosine-phosphate-guanine (CpG) sites and AD pathology and diagnosis. Here, we report relationships between peripheral blood DNA methylation profiles measured using Infinium® MethylationEPIC BeadChip and AD progression in participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.<h4>Results</h4>The rate of cognitive decline from initial DNA sampling visit to subsequent visits was estimated by the slopes of the modified Preclinical Alzheimer Cognitive Composite (mPACC; mPACC<sub>digit</sub> and mPACC<sub>trailsB</sub>) and Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) plots using robust linear regression in cognitively normal (CN) participants and patients with mild cognitive impairment (MCI), respectively. In addition, diagnosis conversion status was assessed using a dichotomized endpoint. Two CpG sites were significantly associated with the slope of mPACC in CN participants (P < 5.79 × 10<sup>-8</sup> [Bonferroni correction threshold]); cg00386386 was associated with the slope of mPACC<sub>digit</sub>, and cg09422696 annotated to RP11-661A12.5 was associated with the slope of CDR-SB. No significant CpG sites associated with diagnosis conversion status were identified. Genes involved in cognition and learning were enriched. A total of 19, 13, and 5 differentially methylated regions (DMRs) associated with the slopes of mPACC<sub>trailsB</sub>, mPACC<sub>digit</sub>, and CDR-SB, respectively, were identified by both comb-p and DMRcate algorithms; these included DMRs annotated to HOXA4. Furthermore, 5 and 19 DMRs were associated with conversion status in CN and MCI participants, respectively. The most significant DMR was annotated to the AD-associated gene PM20D1 (chr1: 205,818,956 to 205,820,014 [13 probes], Sidak-corrected P = 7.74 × 10<sup>-24</sup>), which was associated with both the slope of CDR-SB and the MCI conversion status.<h4>Conclusion</h4>Candidate CpG sites and regions in peripheral blood were identified as associated with the rate of cognitive decline in participants in the ADNI cohort. While we did not identify a single CpG site with sufficient clinical utility to be used by itself due to the observed effect size, a biosignature composed of DNA methylation changes may have utility as a prognostic biomarker for AD progression.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-05-07T22:25:35.655Z","creation":"2025-04-19T08:22:42.08Z"},"accession":"S-EPMC8518178","cross_references":{"pubmed":["34654479"],"doi":["10.1186/s13148-021-01179-2"]}}